Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118582752 | 11858275 | 2 | F | 20151010 | 20160830 | 20151222 | 20160906 | EXP | CH-SM-2015-07530 | CH-GLAXOSMITHKLINE-CH2015177253 | GLAXOSMITHKLINE | 38.28 | YR | F | Y | 0.00000 | 20160906 | MD | CH | CH |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118582752 | 11858275 | 1 | SS | QUETIAPINE. | QUETIAPINE | 1 | Oral | 100 MG, QD | U | 0 | 100 | MG | QD | ||||||
| 118582752 | 11858275 | 2 | SS | FLUOXETINE | FLUOXETINE HYDROCHLORIDE | 1 | Oral | 40 MG, QD | U | 0 | 40 | MG | QD | ||||||
| 118582752 | 11858275 | 3 | PS | LAMOTRIGINE. | LAMOTRIGINE | 1 | Oral | 250 MG, QD | U | 20241 | 250 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 118582752 | 11858275 | 1 | Personality disorder |
| 118582752 | 11858275 | 2 | Personality disorder |
| 118582752 | 11858275 | 3 | Personality disorder |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 118582752 | 11858275 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 118582752 | 11858275 | Abortion induced | |
| 118582752 | 11858275 | Exposure during pregnancy |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |